


Unrivaled leader in addiction treatment with strong growth prospects, solid balance sheet and a potential US listing; \$100m share buyback announced 1Q 2022

Key Facts

Symbol:	INDV (LSE)
52-wk. high:	340 (GBP)
52-wk. low:	139 (GBP)
Market cap:	\$2.9 bil. (US\$)
Cash 1Q'22:	\$1.0 bil.+ (US\$)
LT Debt 1Q'22:	\$238 mil. (US\$)
Fiscal YE:	December
Headquarters:	Richmond, VA
Employees:	800+

Note: Market data as of Apr. 25, 2022

Q1 2022 Net Revenue (Mar. 31, 2022)



+15% Q1 2022 net revenue growth

\$54m Q1 2022 adj. op. profit*

\$776m Net cash & Investments at Q1 2022

\$100m Share buyback announced Q1 2022

*Excludes exceptional items - No exceptional items in Q1 2022

Leadership

Graham Hetherington
Chair

Mark Crossley
Chief Executive Officer

Ryan Preblich
Chief Financial Officer

Investor Relations


Jason Thompson
Jason.Thompson@Indivior.com
Tel: +804-402-7123

Tim Owens
Timothy.Owens@Indivior.com
Tel: +804-263-3978

Who We Are

Indivior is the global leader in medication-assisted treatment for opioid use disorder (OUD), which has worsened during COVID, and has held the number one position in the largest market (US) for over 15 years. The Company also has a strong international presence, serving OUD patients in 40+ countries.

We are leveraging our historic strength in OUD medications, proprietary extended-release delivery platform (ATRIGEL®), strong cash flow generation and balance sheet strength to continue growing our treatment options for addiction.




Source (updated 4/4/2022): Products - Vital Statistics Rapid Release - Provisional Predicted Drug Overdose Data (cdc.gov)

Indivior Approved Products

SUBLOCADE® (buprenorphine extended-release) injection is a once-monthly subcutaneous injection for the treatment of moderate to severe opioid use disorder. Indivior is targeting >\$1 bil. annual peak net revenue opportunity.

SUBLOCADE® Total Annual NR Growth is Strong



PERSERIS® (risperidone) extended-release injection is a once-monthly subcutaneous injection for schizophrenia. Indivior is targeting an annual peak net revenue opportunity of \$200-\$300 million and recently announced that it has doubled its US salesforce for this product to help achieve that goal.

SUBOXONE® (buprenorphine and naloxone) Film and **SUBUTEX®** (buprenorphine) tablet also are used to treat OUD and are taken daily by sublingual administration. These treatments are available in key global markets.

SUBOXONE® is not promoted in US Market; SUBLOCADE®, PERSERIS® and SUBUTEX® are registered trademarks of Indivior UK Limited